BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $BIIB readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06685757-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:TRANSCEND readout (P3) · Biogen $BIIB
DESCRIPTION:A Study to Learn More About the Effects and Safety of Felzartam
 ab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated 
 Rejection (AMR)\n\nPrimary completion date: 2026-12-01 (estimated)\nPhase 
 3 · Other · Antibody-mediated Rejection\nEnrollment: 132 · Sites: 56\n\
 nPrimary completion = last participant's primary-endpoint data collected\;
  topline results usually follow weeks to months later. Sponsor-reported\, 
 often an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.
 html?nct=NCT06685757\nhttps://clinicaltrials.gov/study/NCT06685757
URL:https://datacutoff.com/radar.html?nct=NCT06685757
CATEGORIES:Other,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03958877-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270520
DTEND;VALUE=DATE:20270521
SUMMARY:BIIB017 (peginterferon beta-1a) readout (P3) · Biogen $BIIB
DESCRIPTION:A Study to Evaluate the Safety\, Tolerability\, and Efficacy of
  BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatme
 nt of Relapsing-Remitting Multiple Sclerosis\n\nPrimary completion date: 2
 027-05-20 (estimated)\nOriginally planned: 2023-03-31 (+49.6 months)\nPhas
 e 3 · Neuro · Multiple Sclerosis\, Relapsing-Remitting\nEnrollment: 152 
 · Sites: 65\n\nPrimary completion = last participant's primary-endpoint d
 ata collected\; topline results usually follow weeks to months later. Spon
 sor-reported\, often an estimate. Not investment advice.\n\nhttps://datacu
 toff.com/radar.html?nct=NCT03958877\nhttps://clinicaltrials.gov/study/NCT0
 3958877
URL:https://datacutoff.com/radar.html?nct=NCT03958877
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06935357-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:PREVAIL readout (P3) · Biogen $BIIB
DESCRIPTION:A Study to Learn About the Effects of Felzartamab Infusions on 
 Adults With Immunoglobulin A Nephropathy (IgAN)\n\nPrimary completion date
 : 2027-05-31 (estimated)\nPhase 3 · GI·Renal·Heme · Immunoglobulin A N
 ephropathy (IgAN)\nEnrollment: 454 · Sites: 265\n\nPrimary completion = l
 ast participant's primary-endpoint data collected\; topline results usuall
 y follow weeks to months later. Sponsor-reported\, often an estimate. Not 
 investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06935357\nh
 ttps://clinicaltrials.gov/study/NCT06935357
URL:https://datacutoff.com/radar.html?nct=NCT06935357
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04856982-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270807
DTEND;VALUE=DATE:20270808
SUMMARY:ATLAS readout (P3) · Biogen $BIIB
DESCRIPTION:Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and
  About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Dev
 eloped ALS Symptoms\n\nPrimary completion date: 2027-08-07 (estimated)\nOr
 iginally planned: 2026-08-07 (+12.0 months)\nPhase 3 · Neuro · Amyotroph
 ic Lateral Sclerosis Associated With a SOD1 Gene M…\nEnrollment: 158 · 
 Sites: 32\n\nPrimary completion = last participant's primary-endpoint data
  collected\; topline results usually follow weeks to months later. Sponsor
 -reported\, often an estimate. Not investment advice.\n\nhttps://datacutof
 f.com/radar.html?nct=NCT04856982\nhttps://clinicaltrials.gov/study/NCT0485
 6982
URL:https://datacutoff.com/radar.html?nct=NCT04856982
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05067790-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:ASCEND readout (P3) · Biogen $BIIB
DESCRIPTION:A Study to Learn About the Effect of Higher Doses of Nusinersen
  (BIIB058) Given as Injections to Participants With Spinal Muscular Atroph
 y (SMA) Who Were Previously Treated With R…\n\nPrimary completion date: 
 2027-09-24 (estimated)\nOriginally planned: 2027-06-14 (+3.4 months)\nPhas
 e 3 · Rare · Spinal Muscular Atrophy\nEnrollment: 45 · Sites: 22\n\nPri
 mary completion = last participant's primary-endpoint data collected\; top
 line results usually follow weeks to months later. Sponsor-reported\, ofte
 n an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html
 ?nct=NCT05067790\nhttps://clinicaltrials.gov/study/NCT05067790
URL:https://datacutoff.com/radar.html?nct=NCT05067790
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953583-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20271116
DTEND;VALUE=DATE:20271117
SUMMARY:BRAVE readout (P3) · Biogen $BIIB
DESCRIPTION:A Study to Learn More About the Effects and Long-Term Safety of
  Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia\n\
 nPrimary completion date: 2027-11-16 (estimated)\nPhase 3 · Neuro · Frie
 dreich Ataxia\nEnrollment: 255 · Sites: 34\n\nPrimary completion = last p
 articipant's primary-endpoint data collected\; topline results usually fol
 low weeks to months later. Sponsor-reported\, often an estimate. Not inves
 tment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06953583\nhttps:
 //clinicaltrials.gov/study/NCT06953583
URL:https://datacutoff.com/radar.html?nct=NCT06953583
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
